Evidence Level
Krill oil is distinguished by its phospholipid-bound omega-3 fatty acids, which enhance bioavailability compared to fish oil triglycerides. Ulven et al. (2011) demonstrated that krill oil achieved 68% greater EPA and DHA incorporation into red blood cells at lower doses than fish oil, highlighting the absorption advantage of phospholipids. Bunea et al. (2004) conducted a 12-week randomized controlled trial (RCT) in hyperlipidemic patients, showing krill oil reduced LDL cholesterol by 34%, triglycerides by 11.5%, and increased HDL by 43.5%, outperforming fish oil on multiple endpoints. Sampalis et al. (2003) found significant relief of premenstrual syndrome symptoms with daily krill oil supplementation, while Deutsch (2007) demonstrated that low-dose krill oil (300mg/day) reduced CRP and pain scores in patients with inflammatory conditions.
Recent systematic reviews have further elucidated krill oil's effects. Huang et al. (2023) analyzed 14 trials involving 1,458 participants, finding significant reductions in total cholesterol, LDL-C, and triglycerides but no impact on other cardiovascular risk factors. Ursoniu et al. (2017) meta-analyzed seven RCTs (662 participants), confirming krill oil's ability to lower LDL-C (-15.52 mg/dL, P=0.018) and triglycerides (-14.03 mg/dL, P<0.001). Conversely, Pimentel et al. (2024) reviewed five trials (n=700) and found no significant improvement in knee pain or lipid profiles, though a small benefit for physical function was noted.
Meng et al. (2025) conducted a meta-analysis of five RCTs involving 730 participants with knee osteoarthritis, showing krill oil significantly improved pain, stiffness, and function based on WOMAC assessments but had no effect on visual analog scale scores or blood markers. Kim et al. (2020) performed a network meta-analysis of 64 trials, concluding that krill oil and fish oil have comparable lipid-modifying effects, though both depend on n-3 fatty acid dose for triglyceride reduction.
Overall,